Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Microcapsules provide targeted chemotherapy drug delivery to cancer cells

3
SHARES

Development of infrared light-sensitive microcapsules could be the future in targeted drug delivery for cancer treatment, says new research.

Mesenchymal stem cells labeled with fluorescent molecules.

Mesenchymal stem cells labeled with fluorescent molecules.

Scientists at the Peter the Great Saint-Petersburg Polytechnic University, Russia have developed a drug delivery method targeting cancer cells that could revolutionise chemotherapy by reducing the toxic effects on healthy cells.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Mesenchymal stem cells (MSC) were used by the researchers as the delivery platform. These stem cells can migrate to tumours and react with them. SDF-1 chemokines released by cancerous neoplasms attract MSCs with CXCR4 receptors on their surface.

“The development of drug delivery systems based on living cells is a burning issue in biomed. This strategy provides for the use of cell cultures that can react with tumours. MSC are considered one of the most promising among the potential drug delivery platforms because they are relatively easy to obtain and grow in a lab,” explained Timofey Karpov, co-developer of the method and associate at the Laboratory for Microencapsulation and Controlled Delivery of Biologically Active Compounds.

The researchers developed a technology through which microcapsules of biologically active substances, such as chemotherapeutic agents, could be taken up to MSC and then delivered to tumour sites.

This strategy provides for the use of cell cultures that can react with tumours”

Scientists used vincristine as a sample drug because it can affect different types of tumours and is actively used in chemotherapy. Firstly, vincristine was put into microcapsules made of polymeric compounds and gold nanorods. These microcapsules were then phagocytosed by MSC. Cells containing the capsules were treated with infrared light, causing the gold rods to heat and break down the polymeric structures of the microcapsules. The disintegrating microcapsules released the vincristine into the MSC. When these cells were then released to interact with a tumour, part of the vincristine was released into the intracellular space, allowing it to affect the cancer.

“The new technology for the synthesis of sub- and micron-sized polymeric capsules provides for the packaging of different biologically active substances. Based on it, platforms for the delivery of a wide range of antitumor substances can be developed and drugs for different areas of modern medicine can be created. Infrared light has been widely used for a long time and is almost harmless when the irradiation parameters are set up correctly,” said Karpov.

Results were published in Biomaterials Science Journal.

Share via
Share via